381 related articles for article (PubMed ID: 20724119)
21. The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia.
Chavanet P
Med Mal Infect; 2013 Dec; 43(11-12):451-5. PubMed ID: 24238896
[TBL] [Abstract][Full Text] [Related]
22. Pneumonia due to methicillin-resistant Staphylococcus aureus: clinical features, diagnosis and management.
Tacconelli E; De Angelis G
Curr Opin Pulm Med; 2009 May; 15(3):218-22. PubMed ID: 19373090
[TBL] [Abstract][Full Text] [Related]
23. New antibiotics for healthcare-associated pneumonia.
Neuner EA; Ritchie DJ; Micek ST
Semin Respir Crit Care Med; 2009 Feb; 30(1):92-101. PubMed ID: 19199191
[TBL] [Abstract][Full Text] [Related]
24. Methicillin-resistant Staphylococcus aureus therapy: past, present, and future.
Rodvold KA; McConeghy KW
Clin Infect Dis; 2014 Jan; 58 Suppl 1():S20-7. PubMed ID: 24343828
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of dalbavancin, tigecycline, minocycline, tetracycline, teicoplanin and vancomycin against community-associated and multidrug-resistant hospital-associated meticillin-resistant Staphylococcus aureus.
Huang V; Cheung CM; Kaatz GW; Rybak MJ
Int J Antimicrob Agents; 2010 Jan; 35(1):25-9. PubMed ID: 19900792
[TBL] [Abstract][Full Text] [Related]
26. Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia: implications of the ZEPHyR trial.
Alaniz C; Pogue JM
Ann Pharmacother; 2012 Oct; 46(10):1432-5. PubMed ID: 22947593
[TBL] [Abstract][Full Text] [Related]
27. New and emerging treatment of Staphylococcus aureus infections in the hospital setting.
Moreillon P
Clin Microbiol Infect; 2008 Apr; 14 Suppl 3():32-41. PubMed ID: 18318877
[TBL] [Abstract][Full Text] [Related]
28. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.
Vidaillac C; Leonard SN; Rybak MJ
Int J Antimicrob Agents; 2010 Jun; 35(6):527-30. PubMed ID: 20346632
[TBL] [Abstract][Full Text] [Related]
29. Managing skin and soft-tissue infection and nosocomial pneumonia caused by MRSA: a 2014 follow-up survey.
Dryden M; Andrasevic AT; Bassetti M; Bouza E; Chastre J; Baguneid M; Esposito S; Giamarellou H; Gyssens I; Nathwani D; Unal S; Voss A; Wilcox M
Int J Antimicrob Agents; 2015 Apr; 45 Suppl 1():S1-14. PubMed ID: 25867210
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
[TBL] [Abstract][Full Text] [Related]
31. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections.
Logman JF; Stephens J; Heeg B; Haider S; Cappelleri J; Nathwani D; Tice A; van Hout BA
Curr Med Res Opin; 2010 Jul; 26(7):1565-78. PubMed ID: 20429820
[TBL] [Abstract][Full Text] [Related]
32. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.
Drew RH
Pharmacotherapy; 2007 Feb; 27(2):227-49. PubMed ID: 17253914
[TBL] [Abstract][Full Text] [Related]
33. Trends in incidence of late-onset methicillin-resistant Staphylococcus aureus infection in neonatal intensive care units: data from the National Nosocomial Infections Surveillance System, 1995-2004.
Lessa FC; Edwards JR; Fridkin SK; Tenover FC; Horan TC; Gorwitz RJ
Pediatr Infect Dis J; 2009 Jul; 28(7):577-81. PubMed ID: 19478687
[TBL] [Abstract][Full Text] [Related]
34. What is the best therapeutic approach to methicillin-resistant Staphylococcus aureus pneumonia?
Peyrani P; Ramirez J
Curr Opin Infect Dis; 2015 Apr; 28(2):164-70. PubMed ID: 25692268
[TBL] [Abstract][Full Text] [Related]
35. [Antibiotics for treatment of infections by methicillin-resistant Staphylococcus aureus (MRSA)].
Stahlmann R
Pneumologie; 2014 Oct; 68(10):676-84. PubMed ID: 25290922
[TBL] [Abstract][Full Text] [Related]
36. Current review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens.
Jean SS; Hsueh PR
Expert Opin Pharmacother; 2011 Oct; 12(14):2145-8. PubMed ID: 21895553
[TBL] [Abstract][Full Text] [Related]
37. [Lipopeptides and oxazolidinones--novel antibiotics in MRSA infection treatment].
Pangercić A; Bukovski-Simonoski S; Barsić B
Lijec Vjesn; 2010; 132 Suppl 1():11-3. PubMed ID: 20715711
[TBL] [Abstract][Full Text] [Related]
38. New agents for Staphylococcus aureus endocarditis.
Drees M; Boucher H
Curr Opin Infect Dis; 2006 Dec; 19(6):544-50. PubMed ID: 17075329
[TBL] [Abstract][Full Text] [Related]
39. Methicillin-resistant Staphylococcus aureus infections.
Bartlett JG
Top HIV Med; 2008 Dec; 16(5):151-5. PubMed ID: 19106430
[TBL] [Abstract][Full Text] [Related]
40. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.
Fagon J; Patrick H; Haas DW; Torres A; Gibert C; Cheadle WG; Falcone RE; Anholm JD; Paganin F; Fabian TC; Lilienthal F
Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):753-62. PubMed ID: 10712318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
